# Evan Sussman

> Evan Sussman is the co-founder and CEO of Granata Bio, a Boston-based biopharma company expanding access to fertility care by in-licensing IVF medications proven abroad and bringing them through U.S. clinical development and commercialization. A former fertility business unit head at EMD Serono, he built Granata to be revenue-positive early through a fee-for-service model, then raised a $14M Series A led by GV (Google Ventures), extended it, acquired ovarian-aging biotech Oviva Therapeutics, and struck a strategic investment and co-development deal with Gedeon Richter.

- **Role:** Co-Founder and CEO at Granata Bio
- **Organizations:** Granata Bio, EMD Serono / Merck KGaA, RESOLVE: The National Infertility Association (Corporate Council), American Society for Reproductive Medicine
- **Nationality:** American
- **Education:** BA, Organizational Behavior and Management, Brown University, MBA, Healthcare Leadership, Yale School of Management
- **Known for:** Co-founded and leads Granata Bio, a fertility-focused biopharma with a pipeline spanning multiple IVF product classes, Made Granata Bio revenue-positive early in its life, atypical for biopharma, via a fee-for-service and co-development model, Raised a $14M Series A led by GV (Google Ventures), later extended

## Career timeline

- **2007-2016** — Spent roughly nine years at EMD Serono / Merck KGaA, rising to Marketing and Business Unit Head for U.S. Fertility / Fertility Technologies
- **2014** — Earned MBA in Healthcare Leadership from Yale School of Management
- **2016** — Left EMD Serono to pursue founding a company
- **2018** — Co-founded Granata Bio with Yale classmates and partners; built early revenue via a fee-for-service / co-development model
- **2024** — Closed $14M Series A led by GV (Google Ventures), with CooperSurgical, Gedeon Richter, Alumni Ventures, Amboy Street Ventures and Vibe Bio participating
- **2025** — Acquired Oviva Therapeutics (ovarian aging, lead candidate OVI-586); secured strategic investment and co-development partnership with Gedeon Richter, including BEMFOLA in the U.S.

## Achievements

- Co-founded and leads Granata Bio, a fertility-focused biopharma with a pipeline spanning multiple IVF product classes
- Made Granata Bio revenue-positive early in its life, atypical for biopharma, via a fee-for-service and co-development model
- Raised a $14M Series A led by GV (Google Ventures), later extended
- Acquired Oviva Therapeutics to enter ovarian aging and female reproductive longevity
- Negotiated a strategic equity investment and co-development partnership with Gedeon Richter
- Served on the Corporate Council of RESOLVE and the American Society for Reproductive Medicine

## Latest updates

- **2025-04** — Granata Bio acquired Oviva Therapeutics, adding ovarian-aging candidate OVI-586 with an initial focus on IVF patients with diminished ovarian reserve.
- **2025-05** — Granata Bio secured a strategic equity investment and co-development partnership with Gedeon Richter, including bringing BEMFOLA (FSH) to the U.S. market and a board seat for Richter.

## Links

- Website: https://granata.bio
- LinkedIn: http://www.linkedin.com/in/evanrsussman
- Twitter/X: https://twitter.com/Granata_Bio
- Instagram: https://www.instagram.com/granata.bio/

---

Profile page: https://yespress.io/evan-sussman
Published by YesPress — https://yespress.io
Last updated: 2026-06-12